Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Efficacy and Safety of Degludec Compared to Glargine 300 Units/mL in Insulin-Experienced Patients With Type 2 Diabetes: Trial Protocol Amendment (NCT03078478).

Philis-Tsimikas A, Stratton I, Nørgård Troelsen L, Anker Bak B, Leiter LA.

J Diabetes Sci Technol. 2019 May;13(3):498-506. doi: 10.1177/1932296819841585. Epub 2019 Apr 11.

PMID:
30974986
2.

Efficacy and Safety of Fast-Acting Insulin Aspart in People with Type 1 Diabetes Using Carbohydrate Counting: A Post Hoc Analysis of Two Randomised Controlled Trials.

Rose L, Kadowaki T, Pieber TR, Buchholtz K, Ekelund M, Gorst-Rasmussen A, Philis-Tsimikas A.

Diabetes Ther. 2019 Jun;10(3):1029-1041. doi: 10.1007/s13300-019-0608-4. Epub 2019 Apr 4.

3.

Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.

Zinman B, Bhosekar V, Busch R, Holst I, Ludvik B, Thielke D, Thrasher J, Woo V, Philis-Tsimikas A.

Lancet Diabetes Endocrinol. 2019 May;7(5):356-367. doi: 10.1016/S2213-8587(19)30066-X. Epub 2019 Mar 1. Erratum in: Lancet Diabetes Endocrinol. 2019 Mar 11;:. Lancet Diabetes Endocrinol. 2019 Aug;7(8):e20. Lancet Diabetes Endocrinol. 2019 Nov;7(11):e22.

PMID:
30833170
4.

Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes.

Philis-Tsimikas A, Billings LK, Busch R, Portillo CM, Sahay R, Halladin N, Eggert S, Begtrup K, Harris S.

Diabetes Obes Metab. 2019 Jun;21(6):1399-1408. doi: 10.1111/dom.13666. Epub 2019 Apr 4.

5.

Effect of Insulin Degludec Versus Insulin Glargine U100 on Hypoglycemia in Hispanic Patients With Type 2 Diabetes: Results From the SWITCH 2 Trial.

Chaykin L, Bhargava A, de la Rosa R, Wysham CH, Nørgård Troelsen L, Østoft SH, Philis-Tsimikas A.

Clin Diabetes. 2019 Jan;37(1):73-81. doi: 10.2337/cd18-0016.

PMID:
30705500
6.

Efficacy and tolerability of exenatide once weekly over 7 years in patients with type 2 diabetes: An open-label extension of the DURATION-1 study.

Philis-Tsimikas A, Wysham CH, Hardy E, Han J, Iqbal N.

J Diabetes Complications. 2019 Mar;33(3):223-230. doi: 10.1016/j.jdiacomp.2018.11.012. Epub 2018 Dec 5.

7.

Similar glycaemic control with less nocturnal hypoglycaemia in a 38-week trial comparing the IDegAsp co-formulation with insulin glargine U100 and insulin aspart in basal insulin-treated subjects with type 2 diabetes mellitus.

Philis-Tsimikas A, Astamirova K, Gupta Y, Haggag A, Roula D, Bak BA, Fita EG, Nielsen AM, Demir T.

Diabetes Res Clin Pract. 2019 Jan;147:157-165. doi: 10.1016/j.diabres.2018.10.024. Epub 2018 Nov 16.

8.

Day-to-day fasting self-monitored blood glucose variability is associated with risk of hypoglycaemia in insulin-treated patients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH Trials.

DeVries JH, Bailey TS, Bhargava A, Gerety G, Gumprecht J, Heller S, Lane W, Wysham CH, Zinman B, Bak BA, Hachmann-Nielsen E, Philis-Tsimikas A.

Diabetes Obes Metab. 2019 Mar;21(3):622-630. doi: 10.1111/dom.13565. Epub 2018 Nov 26.

9.

When insulin degludec enhances quality of life in patients with type 2 diabetes: a qualitative investigation.

Weatherall J, Polonsky WH, Lanar S, Knoble N, Håkan-Bloch J, Constam E, Philis-Tsimikas A, Marrel A.

Health Qual Life Outcomes. 2018 May 3;16(1):87. doi: 10.1186/s12955-018-0883-1.

10.

Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trial.

Mathieu C, Bode BW, Franek E, Philis-Tsimikas A, Rose L, Graungaard T, Birk Østerskov A, Russell-Jones D.

Diabetes Obes Metab. 2018 May;20(5):1148-1155. doi: 10.1111/dom.13205. Epub 2018 Feb 4.

11.

Pilot Test of a Culturally Appropriate Diabetes Prevention Intervention for At-Risk Latina Women.

McCurley JL, Fortmann AL, Gutierrez AP, Gonzalez P, Euyoque J, Clark T, Preciado J, Ahmad A, Philis-Tsimikas A, Gallo LC.

Diabetes Educ. 2017 Dec;43(6):631-640. doi: 10.1177/0145721717738020. Epub 2017 Oct 23.

12.

Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial.

Lane W, Bailey TS, Gerety G, Gumprecht J, Philis-Tsimikas A, Hansen CT, Nielsen TSS, Warren M; Group Information; SWITCH 1.

JAMA. 2017 Jul 4;318(1):33-44. doi: 10.1001/jama.2017.7115.

13.

Dulce Digital: An mHealth SMS-Based Intervention Improves Glycemic Control in Hispanics With Type 2 Diabetes.

Fortmann AL, Gallo LC, Garcia MI, Taleb M, Euyoque JA, Clark T, Skidmore J, Ruiz M, Dharkar-Surber S, Schultz J, Philis-Tsimikas A.

Diabetes Care. 2017 Oct;40(10):1349-1355. doi: 10.2337/dc17-0230. Epub 2017 Jun 9.

14.

Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1).

Russell-Jones D, Bode BW, De Block C, Franek E, Heller SR, Mathieu C, Philis-Tsimikas A, Rose L, Woo VC, Østerskov AB, Graungaard T, Bergenstal RM.

Diabetes Care. 2017 Jul;40(7):943-950. doi: 10.2337/dc16-1771. Epub 2017 Mar 29.

PMID:
28356319
15.

A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target Ranges.

King AB, Philis-Tsimikas A, Kilpatrick ES, Langbakke IH, Begtrup K, Vilsbøll T.

Diabetes Technol Ther. 2017 Apr;19(4):255-264. doi: 10.1089/dia.2016.0405. Epub 2017 Mar 10.

16.

REPLACE-BG: A Randomized Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Adults With Well-Controlled Type 1 Diabetes.

Aleppo G, Ruedy KJ, Riddlesworth TD, Kruger DF, Peters AL, Hirsch I, Bergenstal RM, Toschi E, Ahmann AJ, Shah VN, Rickels MR, Bode BW, Philis-Tsimikas A, Pop-Busui R, Rodriguez H, Eyth E, Bhargava A, Kollman C, Beck RW; REPLACE-BG Study Group.

Diabetes Care. 2017 Apr;40(4):538-545. doi: 10.2337/dc16-2482. Epub 2017 Feb 16.

17.

Patient perspectives on whole-genome sequencing for undiagnosed diseases.

Boeldt DL, Cheung C, Ariniello L, Darst BF, Topol S, Schork NJ, Philis-Tsimikas A, Torkamani A, Fortmann AL, Bloss CS.

Per Med. 2017 Jan;14(1):17-25. doi: 10.2217/pme-2016-0050. Epub 2016 Nov 30.

PMID:
29749824
18.
19.

Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 Study).

Aroda VR, Bailey TS, Cariou B, Kumar S, Leiter LA, Raskin P, Zacho J, Andersen TH, Philis-Tsimikas A.

Diabetes Obes Metab. 2016 Jul;18(7):663-70. doi: 10.1111/dom.12661. Epub 2016 May 2. Erratum in: Diabetes Obes Metab. 2016 Sep;18(9):952.

20.

Dulce Wireless Tijuana: A Randomized Control Trial Evaluating the Impact of Project Dulce and Short-Term Mobile Technology on Glycemic Control in a Family Medicine Clinic in Northern Mexico.

Anzaldo-Campos MC, Contreras S, Vargas-Ojeda A, Menchaca-Díaz R, Fortmann A, Philis-Tsimikas A.

Diabetes Technol Ther. 2016 Apr;18(4):240-51. doi: 10.1089/dia.2015.0283. Epub 2016 Feb 25.

21.

Novel approach to inpatient glucometric monitoring and variability in a community hospital setting.

Koziol J, Johnson K, Brenner K, Fortmann A, Morrisey R, Philis-Tsimikas A.

J Diabetes Sci Technol. 2015 Mar;9(2):246-56. doi: 10.1177/1932296814564992. Epub 2014 Dec 23.

22.

Dulce Mothers: an intervention to reduce diabetes and cardiovascular risk in Latinas after gestational diabetes.

Philis-Tsimikas A, Fortmann AL, Dharkar-Surber S, Euyoque JA, Ruiz M, Schultz J, Gallo LC.

Transl Behav Med. 2014 Mar;4(1):18-25. doi: 10.1007/s13142-014-0253-4.

23.

A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON).

Mathieu C, Rodbard HW, Cariou B, Handelsman Y, Philis-Tsimikas A, Ocampo Francisco AM, Rana A, Zinman B; BEGIN: VICTOZA ADD-ON (NN1250-3948) study group.

Diabetes Obes Metab. 2014 Jul;16(7):636-44. doi: 10.1111/dom.12262. Epub 2014 Feb 11.

PMID:
24443830
24.

Implementing community-based diabetes programs: the scripps whittier diabetes institute experience.

Philis-Tsimikas A, Gallo LC.

Curr Diab Rep. 2014 Feb;14(2):462. doi: 10.1007/s11892-013-0462-0.

25.

A new option for glycemic control: insulin degludec, a new-generation basal insulin with an ultralong duration of action.

Drab SR, Philis-Tsimikas A.

Pharmacotherapy. 2014 Mar;34(3):291-302. doi: 10.1002/phar.1361. Epub 2013 Oct 17. Review.

PMID:
24132869
26.

Initiating basal insulin therapy in type 2 diabetes: practical steps to optimize glycemic control.

Philis-Tsimikas A.

Am J Med. 2013 Sep;126(9 Suppl 1):S21-7. doi: 10.1016/j.amjmed.2013.06.010. Review.

PMID:
23953076
27.

Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial.

Rodbard HW, Cariou B, Zinman B, Handelsman Y, Philis-Tsimikas A, Skjøth TV, Rana A, Mathieu C; BEGIN Once Long trial investigators.

Diabet Med. 2013 Nov;30(11):1298-304. doi: 10.1111/dme.12303. Epub 2013 Sep 30.

28.

Insulin degludec once-daily in type 2 diabetes: simple or step-wise titration (BEGIN: once simple use).

Philis-Tsimikas A, Brod M, Niemeyer M, Ocampo Francisco AM, Rothman J.

Adv Ther. 2013 Jun;30(6):607-22. doi: 10.1007/s12325-013-0036-1. Epub 2013 Jun 29.

29.

Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents.

Philis-Tsimikas A, Del Prato S, Satman I, Bhargava A, Dharmalingam M, Skjøth TV, Rasmussen S, Garber AJ.

Diabetes Obes Metab. 2013 Aug;15(8):760-6. doi: 10.1111/dom.12115. Epub 2013 May 6.

30.

Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long).

Zinman B, Philis-Tsimikas A, Cariou B, Handelsman Y, Rodbard HW, Johansen T, Endahl L, Mathieu C; NN1250-3579 (BEGIN Once Long) Trial Investigators.

Diabetes Care. 2012 Dec;35(12):2464-71. doi: 10.2337/dc12-1205. Epub 2012 Oct 5.

31.

Precision, accuracy, and user acceptance of the OneTouch SelectSimple blood glucose monitoring system.

Philis-Tsimikas A, Chang A, Miller L.

J Diabetes Sci Technol. 2011 Nov 1;5(6):1602-9.

32.

Peer-led diabetes education programs in high-risk Mexican Americans improve glycemic control compared with standard approaches: a Project Dulce promotora randomized trial.

Philis-Tsimikas A, Fortmann A, Lleva-Ocana L, Walker C, Gallo LC.

Diabetes Care. 2011 Sep;34(9):1926-31. doi: 10.2337/dc10-2081. Epub 2011 Jul 20.

33.

Glycemic control among Latinos with type 2 diabetes: the role of social-environmental support resources.

Fortmann AL, Gallo LC, Philis-Tsimikas A.

Health Psychol. 2011 May;30(3):251-8. doi: 10.1037/a0022850.

34.

Type 2 diabetes care and insulin intensification: is a more multidisciplinary approach needed? Results from the MODIFY survey.

Cuddihy RM, Philis-Tsimikas A, Nazeri A.

Diabetes Educ. 2011 Jan-Feb;37(1):111-23. doi: 10.1177/0145721710388426. Epub 2010 Dec 3.

PMID:
21131599
35.
36.

Are patients' initial experiences at the diagnosis of type 2 diabetes associated with attitudes and self-management over time?

Polonsky WH, Fisher L, Guzman S, Sieber WJ, Philis-Tsimikas A, Edelman SV.

Diabetes Educ. 2010 Sep-Oct;36(5):828-34. doi: 10.1177/0145721710378539. Epub 2010 Aug 20.

PMID:
20729511
37.

Outcomes from a culturally tailored diabetes prevention program in Hispanic families from a low-income school: Horton Hawks Stay Healthy (HHSH).

Coleman KJ, Ocana LL, Walker C, Araujo RA, Gutierrez V, Shordon M, Oratowski-Coleman J, Philis-Tsimikas A.

Diabetes Educ. 2010 Sep-Oct;36(5):784-92. doi: 10.1177/0145721710377360. Epub 2010 Jul 22.

PMID:
20651100
38.

Teen peer educators and diabetes knowledge of low-income fifth grade students.

Coleman KJ, Clark AY, Shordon M, Ocana LL, Walker C, Araujo RA, Oratowski-Coleman J, Philis-Tsimikas A.

J Community Health. 2011 Feb;36(1):23-6. doi: 10.1007/s10900-010-9276-z.

PMID:
20496001
39.

An update on the use of insulin detemir, with a focus on type 2 diabetes (drug evaluation update).

Philis-Tsimikas A.

Expert Opin Pharmacother. 2008 Aug;9(12):2181-95. doi: 10.1517/14656566.9.12.2181 . Review.

PMID:
18671472
40.

Improving treatment of depression among Latinos with diabetes using project Dulce and IMPACT.

Gilmer TP, Walker C, Johnson ED, Philis-Tsimikas A, Unützer J.

Diabetes Care. 2008 Jul;31(7):1324-6. doi: 10.2337/dc08-0307. Epub 2008 Mar 20.

41.
42.

Cost-effectiveness of diabetes case management for low-income populations.

Gilmer TP, Roze S, Valentine WJ, Emy-Albrecht K, Ray JA, Cobden D, Nicklasson L, Philis-Tsimikas A, Palmer AJ.

Health Serv Res. 2007 Oct;42(5):1943-59.

43.

Prevalence of sleep apnea in a population of adults with type 2 diabetes mellitus.

Einhorn D, Stewart DA, Erman MK, Gordon N, Philis-Tsimikas A, Casal E.

Endocr Pract. 2007 Jul-Aug;13(4):355-62.

PMID:
17669711
44.

Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weight.

Karl D, Philis-Tsimikas A, Darsow T, Lorenzi G, Kellmeyer T, Lutz K, Wang Y, Frias JP.

Diabetes Technol Ther. 2007 Apr;9(2):191-9.

PMID:
17425446
45.

Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes.

Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B.

Clin Ther. 2006 Oct;28(10):1569-81. Erratum in: Clin Ther. 2006 Nov;28(11):1967.

PMID:
17157113
46.

Glycemic control with insulin glargine as part of an ethnically diverse, community-based diabetes management program.

Philis-Tsimikas A, Zhang Q, Walker C.

Am J Ther. 2006 Nov-Dec;13(6):466-72.

PMID:
17122525
47.

The incretin effect and its potentiation by glucagon-like peptide 1-based therapies: a revolution in diabetes management.

Roges OA, Baron M, Philis-Tsimikas A.

Expert Opin Investig Drugs. 2005 Jun;14(6):705-27. Review.

PMID:
16004598
48.

Predictors of glycemic control among patients with Type 2 diabetes: a longitudinal study.

Benoit SR, Fleming R, Philis-Tsimikas A, Ji M.

BMC Public Health. 2005 Apr 17;5:36.

49.

Outcomes of Project Dulce: a culturally specific diabetes management program.

Gilmer TP, Philis-Tsimikas A, Walker C.

Ann Pharmacother. 2005 May;39(5):817-22. Epub 2005 Mar 15.

PMID:
15769828
50.

Predictors of dropouts from a San Diego diabetes program: a case control study.

Benoit SR, Ji M, Fleming R, Philis-Tsimikas A.

Prev Chronic Dis. 2004 Oct;1(4):A10. Epub 2004 Sep 15.

Supplemental Content

Loading ...
Support Center